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SUMMARY
Fatty acid biosynthesis has been viewed as an important biological function of and therapeutic target
for Plasmodium falciparum asexual blood stage infection. This apicoplast-resident type II pathway,
distinct from the mammalian type I process, includes FabI. Here, we report synthetic chemistry and
transfection studies concluding that Plasmodium FabI is not the target of the antimalarial activity of
the bacterial FabI inhibitor triclosan. Disruption of fabI in P. falciparum or the rodent parasite P.
berghei does not impede blood stage growth. In contrast, mosquito-derived fabI-deficient P.
berghei sporozoites are markedly less infective for mice and typically fail to complete liver stage
development in vitro. This is characterized by an inability to form intra-hepatic merosomes that
normally initiate blood stage infections. These data illuminate key differences between liver and
blood stage parasites in their requirements for host versus de novo synthesized fatty acids, and create
new prospects for stage-specific antimalarial interventions.
*Corresponding author: df2260@columbia.edu; Tel: +1 212 305 0816; FAX: +1 212 305 4038.¶These authors contributed equally to this work.†Current Address: Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA≠Current Address: Regeneron, Tarrytown, NY 10591, USA
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Cell Host Microbe. Author manuscript; available in PMC 2009 December 11.
Published in final edited form as:
Cell Host Microbe. 2008 December 11; 4(6): 567–578. doi:10.1016/j.chom.2008.11.001.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
81
87
1 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
INTRODUCTION
Plasmodium parasites must coordinate the salvage of host factors with de novo biosynthesis
pathways in order to meet the unique demands of each intracellular stage of their life cycle. In
mammals, this begins with the bite of an infected Anopheles mosquito. The intradermally
injected sporozoites (SPZ) then migrate to the liver and invade hepatocytes (Amino et al.,
2008). Liver stage development involves the transformation of an intracellular sporozoite,
bounded by an inner parasite plasma membrane (PPM) and an outer parasitophorous vacuolar
membrane (PVM), into a liver stage trophozoite. This stage undergoes prolific nuclear division
and membrane synthesis, with commensurate metabolic demands. In the case of P.
falciparum, the most lethal etiologic agent of human malaria, each infected hepatocyte
produces up to 10,000–30,000 merozoites, contained within an intra-hepatic merosome, over
6–7 days.
Liberated liver stage merozoites enter the bloodstream where they invade red blood cells (RBC)
and initiate the asexual blood stages that cause clinical manifestations of disease. Parasite
development inside these anucleate cells displays several fundamental differences from the
liver stages (Silvie et al., 2008b). These include the ability of asexual blood stage parasites to
degrade hemoglobin and detoxify heme (processes that are key to the mode of action of multiple
antimalarials), and also to modify the host cell membrane such that the infected RBC can
sequester in the microvasculature. The entire asexual cycle is completed within 48 hr,
producing 8–24 infectious merozoites per infected RBC. In contrast to the small liver stage
inoculum, numbers of infected RBC can exceed 1012 per host (Greenwood et al., 2008). Intra-
erythrocytic parasites can also transform into sexual gametocyte stages. Upon their ingestion
by a feeding Anopheles mosquito, these parasites undergo fertilization and sexual
recombination, ultimately producing oocyst SPZ that migrate to the salivary glands, ready to
initiate a new round of infection.
The prodigious proliferative capacity of malarial parasites necessitates access to an abundant
source of fatty acids (FA). These carboxylic acid-linked acyl chains are required for the
production of lipid species that are essential for parasite membrane and lipid body biogenesis
(Palacpac et al., 2004). FA are also required for glycosylphosphatidylinositol (GPI) moieties
that serve to anchor parasite membrane proteins (Gilson et al., 2006). FA and phospholipid
concentrations are respectively 6–fold and 3 to 5–fold higher in infected compared to
uninfected RBC. This was initially attributed to FA salvage from host plasma, as parasites were
thought to be incapable of de novo synthesis (Vial and Ancelin, 1992). The paradigm changed
with the discovery that P. falciparum harbors components of a type II FA biosynthesis (FAS-
II) pathway (Ralph et al., 2004). A subsequent study reported that P. falciparum asexual blood
stages had FAS-II activity, producing FA with chain lengths of C10 to C14 (Surolia and Surolia,
2001). FAS-II enzymes have been localized to the apicoplast, a non-photosynthetic plastid
organelle of cyanobacterial origin. In addition to FA biosynthesis, the apicoplast harbors unique
pathways for the synthesis of isoprenoids and heme, and shares lipoic acid synthesis and
salvage pathways with the mitochondria. The discovery that antibiotics with antimalarial
activity inhibit apicoplast function has highlighted the therapeutic potential of targeting this
organelle (Ralph et al., 2004).
The FAS-II pathway in Plasmodium has been of particular therapeutic interest because it is
distinct from the type I (FAS-I) pathway found in mammals. FAS-II requires acetyl-Coenzyme
A (CoA), which can be converted from pyruvate by the pyruvate dehydrogenase complex.
Acetyl-CoA carboxylase converts acetyl-CoA to malonyl-CoA, which is tethered to an acyl
carrier protein (ACP) by malonyl-CoA:ACP transacylase (FabD). This produces malonyl-
ACP, which in conjunction with acetyl-CoA is acted upon by β-ketoacyl-ACP synthase III
(Fab H) to form β-ketoacyl-ACP. This precursor enters the FAS-II elongation cycle, mediated
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by FabB/F (β-ketoacyl-acyl-carrier-protein (ACP) synthase), FabG (β-ketoacyl-ACP
reductase), FabZ/A (β-hydroxyacyl-ACP dehydratase) and FabI (trans-2-enoyl-ACP
reductase). These four FAS-II enzymes iteratively catalyze the addition of two carbon chains
to a growing fatty acyl carbon chain, via condensation, reduction, dehydration and reduction
steps, respectively. In contrast, FAS-I contains all four enzymatic functionalities within a
single, large polypeptide (Mazumdar and Striepen, 2007).
Studies from pathogenic bacteria have confirmed the therapeutic value of FAS-II inhibitors
(Zhang et al., 2006). These include triclosan, a microbicide widely used in consumer products.
A highly cited report describing triclosan antimalarial activity in vitro against P. falciparum
and in vivo against the rodent parasite P. berghei, directed against the pathogenic asexual blood
stages, generated tremendous interest in this compound and its predicted target - FabI (Surolia
and Surolia, 2001). This led to the structural elucidation of the P. falciparum FabI (PfFabI;
PlasmoDB gene ID PFF0730c) homotetramer to which triclosan:NAD+ adducts bind in the
active site, and propelled structure-guided efforts to develop novel antimalarials based on
triclosan (Freundlich et al., 2007; Muralidharan et al., 2003; Perozzo et al., 2002). Here, we
report our investigations into a series of analogs designed to improve on the antimalarial
properties of triclosan and our ensuing studies that focused on the biological role of FabI.
RESULTS
Triclosan Activity Against Plasmodium Asexual Blood Stages Does Not Correlate With its
Inhibition of Purified Recombinant FabI
We initiated a structure-guided medicinal chemistry program to improve the potency of
triclosan by modifying substituents around its diaryl ether scaffold. This led us to synthesize
80 analogs (Figure 1A), for which only a single position was modified to reduce the likelihood
of creating off-target activity. These analogs, grouped by the carbon position that was modified
(see Figure 1B inset; detailed in Table S1 in the Supplemental Data available with this article
online), were evaluated for their inhibition of cultured P. falciparum asexual blood stage
parasites (3D7 and Dd2 lines), and separately, for inhibition of purified PfFabI enzyme.
Activities were compared against triclosan, which yielded mean IC50 values of 1.8 μM and 2.1
μM against the 3D7 and Dd2 lines and an EC50 value of 73 nM against purified PfFabI.
Individual analog series showed substantial differences in their inhibitory activities (Figure
1A). The 2′-position analog series afforded the most potent inhibitors in the parasite assays,
yet showed minimal inhibition of PfFabI. Modifications at the 4′- or 5- position afforded a few
modest improvements in efficacy, mostly against PfFabI, whereas changes at the 4- or 6-
position generally produced less potent inhibitors. We also noted that compound series with
similar mean potencies against PfFabI (e.g. the 4′- and 5- position analogs) exhibited nearly
10–fold differences in their mean antiparasitic activities. Further analysis revealed a lack of a
significant association between enzyme and parasite inhibition, as evidenced by the Pearson
r2 values of 0.13 and 0.15 obtained by plotting these data for 3D7 and Dd2 respectively (Figure
1B; data not shown). While chemical properties such as membrane permeability and solubility
might obscure close whole-cell and enzyme correlations for on-target compounds, our data
nonetheless raised doubts that triclosan analogs acted against asexual blood stage parasites by
inhibiting PfFabI.
In parallel with these studies, we re-evaluated the in vivo efficacy of triclosan. A previous report
had documented that four days of subcutaneous injections of triclosan at 3 mg/kg/day could
suppress P. berghei parasitemia by 75%, and that injections with doses of 38 mg/kg/day cured
the infected mice with 100% efficacy (Surolia and Surolia, 2001). We tested both oral (PO)
and subcutaneous (SC) routes of triclosan, administered over a range of 16 to 512 mg/kg/day,
for three days with a twice-daily divided dose, to mice infected three days prior with P.
berghei (KBG-173 line). Parasitemias were recorded on day 6 post-infection (i.e. one day after
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the last dose of triclosan) and were 61% or 57% (for PO or SC respectively) in control (infected
and placebo-treated) mice. Increasing the triclosan concentrations from 16 to 128 mg/kg/day
caused a dose-dependent decrease in parasitemias, to a minimum of 27% or 13% with 128 mg/
kg/day triclosan administered PO or SC respectively (Figure 1C). Higher doses failed to further
suppress the parasitemias.
Assessment of survival showed that all control mice died by days 10 (PO) or 12 (SC) (Figure
1D, E). Oral administration of 64 mg/kg/day triclosan yielded a slight extension in survival
times, and doses of 128 or 256 mg/kg/day produced 30% survival rates measured at day 31.
Increasing the dose to 512 mg/kg/day led to some early mortality and decreased overall survival
rates, suggesting some toxicity. Via the SC route, triclosan was moderately more effective,
although survival never exceeded 50%. In vivo tests with several analogs (compounds 18, 20,
22, 41, 45 & 60 in Table S1), whose in vitro potencies were comparable to triclosan, revealed
no improvements over the parent compound (A. Ager and D. Jacobus, unpublished data). We
concluded that, under our experimental conditions, triclosan had reduced antimalarial potency
in vivo as compared to the earlier report (Surolia and Surolia, 2001). Furthermore, the in
vitro potency of triclosan analogs did not correlate with their inhibition of FabI enzymatic
activity.
Transgene Expression of a Mutant FabI That is Biochemically Resistant to Triclosan Does
Not Decrease P. falciparum Susceptibility to This Agent
To further investigate the role of FabI in the mode of action of triclosan, we transfected P.
falciparum asexual blood stage parasites with plasmids expressing V5 epitope-tagged forms
of pffabI that were either wild type (WT) or that encoded the A217V mutation. This mutation
was selected because it confers a 7,000-fold decrease in triclosan binding affinity for
recombinant PfFabI (Kapoor et al., 2004). To express these pffabI transgenes, we selected the
calmodulin (PF14_0323) promoter, which is highly active in asexual blood stages
(www.PlasmoDB.org). Integration of these plasmids (named pffabI(A217V)-V5-attP and
pffabI(WT)-V5-attP; Table 1) into the P. falciparum genome was achieved using the Bxb1
serine integrase-mediated attBxattP system of recombination, which delivers transgenes into
the attB-marked cg6 locus and results in a genetically and phenotypically homogeneous
population of recombinant parasite lines (Nkrumah et al., 2006). The transfections, performed
with Dd2attB and 3D7attB parasites, produced the transgenic lines PffabI(A217V)Dd2, PffabI
(WT)Dd2, PffabI(A217V)3D7 and PffabI(WT)3D7 (Table 1; Figure S1A). Southern blot analysis
confirmed correct integration of the pffabI transgenic copies into the cg6-attB site and the
predicted organization of the endogenous pffabI locus (Figure S1B; data not shown). Western
blot analysis with anti-V5 antibodies revealed the expression of ~46 kDa V5-tagged PfFabI
proteins in all four lines (Figure S1C). Immunofluorescence assays with the PffabI
(A217V)Dd2 line showed co-localization of PfFabI-V5 and the apicoplast-resident acyl carrier
protein (ACP) in a compartment distinct from the nucleus (stained with Hoechst 33342) and
the mitochondrion (stained with MitoTracker Red), thus confirming trafficking of V5-tagged
PfFabI to the apicoplast (Figure 2A, B). We proceeded to measure the triclosan susceptibility
of our transgenic and parental lines. Results from drug susceptibility assays showed no
significant difference in either IC50 or IC90 values between recombinant lines expressing
mutant or WT PfFabI (Figure 2C; values provided in legend).
P. falciparum FabI is Not Expressed at Detectable Levels in Asexual Blood Stage Parasites
Subsequent Northern blot experiments detected the presence of pffabI transcripts only in the
transgenic lines (PffabI(A217V)Dd2, PffabI(WT)Dd2, PffabI(A217V)3D7 and PffabI(WT)3D7)
that express an additional pffabI copy from the highly active mature stage calmodulin promoter,
and not in the lines expressing endogenous pffabI alone (Dd2attB, Dd2, 3D7attB and 3D7; Figure
2D). We attribute the apparent increase in pffabI transcripts in the PffabI(A217V)Dd2 and
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PffabI(A217V)3D7 lines, compared to the PffabI(WT)Dd2 and PffabI(WT)3D7 lines, to the
higher proportions of mature stage parasites in the former at the time of RNA harvest. To
confirm the lack of endogenous pffabI expression at the protein level, we raised rabbit
polyclonal antiserum against purified recombinant PfFabI. Western blot analysis with extracts
of parasites expressing calmodulin promoter-driven PfFabI-V5 showed that the antiserum and
monoclonal antibodies against the V5 epitope tag both detected a ~46 kDa protein (Figure 2E).
The anti-PfFabI antiserum did not detect any protein in extracts of control parasites expressing
pffabI from its endogenous promoter (Figure 2F).
FabI is Not Required for Normal Propagation of P. falciparum Asexual Blood Stage Parasites
and its Absence Does Not Alter Parasite Susceptibility to Triclosan
These findings led us to question whether pffabI is required for P. falciparum asexual blood
stage growth in vitro. To test this, we designed a DNA construct (pcam-bsd-ΔpffabI), which
contained an internal region of the pffabI coding sequence (encoding amino acids 98 to 295)
such that homologous recombination between this fragment and the endogenous pffabI gene
would separate the full-length sequence into two truncated fragments (Figure S2A). The
upstream fragment lacked the 3′ end of the gene corresponding to amino acids 296–432 (thereby
eliminating the β6–β9 helices and β6–β7 strands that contribute to forming the NADH-binding
Rossman fold). The downstream fragment lacked a promoter and the first 98 amino acids that
included the bipartite targeting sequence predicted to be required for protein trafficking to the
apicoplast (Perozzo et al., 2002). Transfection of cultured Dd2 parasites with this knockout
construct resulted in the generation of parasite clones (PfΔfabI1 and PfΔfabI2) in which the
pffabI gene had been disrupted by single site crossover and plasmid integration, as confirmed
by PCR and Southern blot analyses (Table 1; Figure S2B, C). Measurements of parasitemia
over a two-month period revealed equivalent growth rates (averaging 5.0 to 5.6–fold
multiplication per 48 hr cycle of RBC invasion, intracellular development and egress) between
these knockout clones and parental Dd2. These data demonstrated the non-essentiality of
pffabI for asexual blood stage propagation, and implied that the activity of triclosan against
these stages could not result from inhibition of PfFabI. This was confirmed with drug
susceptibility assays that revealed similar triclosan susceptibilities in PfΔfabI1, PfΔfabI2 and
the parental Dd2 line (mean ± SEM IC50 values of 2.2±0.2, 2.4±0.3 and 2.1±0.3 μM
respectively, derived from three separate experiments performed in duplicate).
Deletion of P. berghei fabI, the pffabI Ortholog, Does Not Affect Propagation of Blood Stage
Parasites In Vivo
Our P. falciparum in vitro data led us to examine whether this protein was essential for
proliferation of asexual blood stages in vivo. For this, we used the highly virulent P. berghei
ANKA rodent malaria model. Comparisons of the amino acid sequences of PfFabI and its
predicted ortholog in P. berghei, PbFabI (PB000088.02.0), revealed 62% identity and 74%
similarity (Figure S3A). Bacterial expression and purification of PbFabI enabled us to elucidate
its structure at 2.5Å resolution. Superimposing this with the known PfFabI structure (Perozzo
et al., 2002) revealed a nearly identical organization with each subunit in the tetramer
containing 9 α-helices and 7 β-sheets (Figure S3B). Detailed inspection of the active sites
revealed these to be indistinguishable (Figure S3C). From these studies, we can confidently
predict that PbFabI and PfFabI fulfill the same enzymatic function for Plasmodium parasites.
We transfected P. berghei ANKA parasites with a DNA construct termed pLitmus28-
ΔpbfabI. This was designed to permit double crossover, resulting in complete deletion of the
endogenous pbfabI locus and its replacement by the T. gondii dihydrofolate reductase-
thymidylate synthase (Tgdhfr-ts) selectable marker that confers resistance to pyrimethamine.
From this transfection, we selected mutant parasites and used limiting dilution to obtain a clone,
termed PbΔfabI (Table 1). PCR and Southern blot analyses confirmed correct integration of
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the DNA construct and deletion of the pbfabI coding sequence in this clone (Figure S4A, C,
D). As a “knock-in” control, we utilized a similar double crossover strategy to replace the
endogenous gene with a construct that reinserted a full-length, functional pbfabI gene under
control of the endogenous promoter, as well as the Tgdhfr-ts selectable marker. This yielded
the PbfabIRec clone, whose recombinant locus was confirmed by PCR and Southern blot
hybridization (Figure S4B, C, D). Measurements of parasitemia in mice infected with
PbΔfabI, PbfabIRec or parental ANKA revealed similar rates of proliferation, calculated to be
4.8±1.4, 5.5±2.2 and 4.4±1.7 per 24 hr cycle respectively in two comparative experiments with
groups of 4 mice each (values represents means±SD; Figure S4E). These values were not
statistically different between lines, as determined by Mann-Whitney tests. Thus, there was no
substantial decrease in asexual blood stage in vivo viability upon deletion of pbfabI.
Drug susceptibility assays with P. berghei asexual blood stages tested ex vivo showed
equivalent triclosan IC50 values in the PbΔfabI, PbfabIRec and ANKA lines (means±SEM of
1.4±0.1, 1.5±0.2 and 1.2±0.1 μM respectively). Control assays with the unrelated antimalarial
chloroquine produced IC50 values of 11.0±0.1, 13.0±0.6 and 10.4±0.3 nM in these lines
respectively. These results, combined with the P. falciparum studies, conclusively demonstrate
that the blood stage activity of triclosan is not attributable to inhibition of FabI.
Plasmodium Asexual Blood Stage Parasites Lacking FabI Can Produce FA Species
The availability of parasite lines lacking FabI allowed us to determine whether Plasmodium
asexual blood stages utilize the FAS-II pathway to synthesize FA de novo. We incubated
synchronized trophozoite stage P. falciparum and P. berghei control and fabI knockout
parasites with [14C]-labeled acetate, a radiolabeled FA precursor, then extracted the free FA
that had incorporated this substrate and analyzed them by reversed-phase High Performance
Liquid Chromatography (HPLC). In P. falciparum, this led us to detect radiolabeled C16 and
C18 FA in both the PfΔfabI1 and Dd2 lines (Figure 3A, B). Thus, extension of FA could occur
in the absence of the key FAS-II enzyme FabI. In a separate experiment, we incubated
PfΔfabI1 and other P. falciparum lines with [14C]-labeled acetate, extracted their FA and
analyzed them by reversed-phase thin layer chromatography. This confirmed the production
of radiolabeled C16 and C18 independently of FabI (Figure S2D). We note that these findings
are in contrast with an earlier report that P. falciparum asexual blood stage parasites synthesize
C10 to C14 FA (Surolia and Surolia, 2001).
[14C]-acetate incorporation studies with the P. berghei lines produced evidence of de novo FA
elongation with PbΔfabI parasites, with no visible difference between the PbΔfabI and parental
ANKA lines in terms of the lengths of FA that were produced (Figure 3C, D). In contrast to
P. falciparum, the rodent parasites synthesized FA chain lengths of C12 to C24. No radiolabeled
FA were observed with rodent or human uninfected RBC controls (data not shown). These
data provide evidence that the two Plasmodium species differ in the range of FA that they can
extend de novo; yet they share the common characteristic that FabI is not required.
P. berghei Sporozoites Lacking FabI Are Markedly Attenuated in Their Ability to Progress to
Asexual Blood Stage Infections
The availability of a P. berghei line (PbΔfabI) lacking FabI made it possible to explore the role
of this protein in other stages of the parasite life cycle. We observed that gametocyte production,
gamete fertilization, and the subsequent development of ookinetes and oocysts appeared
unaffected by the absence of FabI, as judged by the similar numbers of oocysts that developed
in Anopheles stephensi mosquitoes fed on mice infected with the PbΔfabI, PbfabIRec or ANKA
lines (data not shown). In two separate experiments, we observed no difference in the numbers
of oocyst and salivary gland SPZ produced by these lines (data not shown).
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To determine whether FabI plays a role in the infectivity of SPZ to the mammalian host, salivary
gland SPZ were dissected and inoculated into the tail vein of C57BL/6 mice. This inbred strain
of mouse was chosen as it is more susceptible than other inbred or outbred mouse strains to
P. berghei SPZ infections (Scheller et al., 1994). Experiments were performed on three separate
occasions and were highly reproducible. Intravenous injections of 1,000 ANKA or
PbfabIRec SPZ produced patent blood stage infections that were microscopically detectable in
16/16 and 15/15 mice by day five (Table 2). In contrast, injection of 1,000 PbΔfabI SPZ
produced a blood stage infection in only 5/16 mice, with the infected mice showing a delay in
patency of 4 days. Increasing the PbΔfabI inoculum to 10,000 SPZ resulted in patent infections
in 13/15 mice, with those mice again showing an average delay of 4 days compared to controls.
We also assayed the infectivity of SPZ delivered by mosquito bite, to test for any defect in SPZ
tissue traversal and migration from the dermis to the liver (Silvie et al., 2008b). Groups of 20
infected mosquitoes were allowed to feed on each mouse, with 5 mice tested per P. berghei
line. Based on earlier studies, we estimate that each infected mosquito intradermally delivers
~120 SPZ (Medica and Sinnis, 2005), yielding an approximate inoculum of 2,000 SPZ. Results
showed that each mouse infected with ANKA or PbfabIRec parasites, as well as 4 of the 5 mice
infected with PbΔfabI SPZ, developed a patent blood stage infection. However, the latter group
showed a 5-day delay (Table 2).
Taken together, the data demonstrate that P. berghei parasites lacking FabI produce SPZ that
are highly attenuated in their infectivity to the mammalian host. We note that all “breakthrough”
PbΔfabI asexual blood stage infections became fulminant and lethal by days 20–29. This
suggests that once PbΔfabI parasites developed into blood stages, they showed no loss of
virulence compared to WT parasites. PCR analysis of breakthrough infections confirmed that
they resulted from PbΔfabI parasites, and not from contamination with ANKA or PffabIRec
parasites (Figure S4F).
PbΔfabI Sporozoites Typically Fail to Produce Infectious Mature Liver Stage Parasites
To investigate the cause of this decreased infectivity of PbΔfabI SPZ, we first examined cell
traversal and invasion of hepatocytes. The former occurs when SPZ transit through cells prior
to initiating liver stage development by forming a parasitophorous vacuole inside the invaded
cell (Silvie et al., 2008b). In two independent experiments, rates of cell traversal were similar,
with a mean of 9–13 dextran positive (i.e. traversed) cells per field. PbΔfabI and PbfabIRec
lines were also found to be equally competent for invasion, with 34–38% success in invading
Hepa 1–6 cells. We next assessed the maturing liver stage parasites. At 24, 36 or 48 hr post-
invasion, PbΔfabI and PbfabIRec parasites stained with antibodies specific for the P. berghei
cytosolic protein HSP70 (PB000817.02.0) showed equivalent numbers and developmental
stages (data not shown). We also tested for fabI transcription in these stages. RT-PCR studies
from infected Hepa 1–6 cells harvested 40 hr post-invasion revealed pbfabI mRNA transcripts
in PbfabIRec but not PbΔfabI liver stage parasites (Figure S4G). These results indicate that
fabI is normally transcribed by liver stage parasites, however the lack of expression in
PbΔfabI parasites did not affect SPZ cell traversal, invasion of hepatocytes, or the initial stages
of intra-hepatic development.
We proceeded to investigate later stages of liver stage maturation using the HepG2 hepatoma
cell line, which is able to support SPZ invasion and liver stage development through to the
production of merozoites that are infectious for RBC. Immunofluorescence assays (IFAs) with
mature hepatic stages were performed with antibodies that recognize the P. berghei parasite
proteins Exp1 (PB000484.01.0) or MSP1 (PB000172.01.0). Exp1 is expressed throughout
trophozoite development and schizogony and is exported into the parasitophorous vacuolar
membrane (PVM) that separates the parasite from the host cell cytosol. In late liver stages, the
Exp1-positive PVM is typically observed as a closed circular structure around the multiplying
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parasite nuclei (Sturm et al., 2006). In schizont stages, MSP1 is expressed and becomes
integrated into the parasite plasma membrane (PPM). The PPM invaginates around pockets of
parasite material during the cytomere stage, and ultimately forms the membrane of individual
merozoites (Sturm et al., 2008).
These antibodies revealed a striking difference between ANKA and PbΔfabI parasites very
late in their liver stage development. At 60 hr post SPZ invasion of HepG2 cells, 59% of the
ANKA parasites were found to have developed into an advanced parasite stage marked by
MSP1-positive PPM invaginations (Figure 4A; Figure S5A). Many of these parasites were
observed at the cytomere stage in which the PPM surrounded large groups of parasite nuclei
(see row 2 in Figure S5A). The remaining 41% of parasites were MSP1-negative, indicating
either delayed or aberrant development. In contrast, almost all PbΔfabI liver stage parasites
(99.5%) were negative for MSP1 staining, despite having initiated their development inside
an Exp1-positive PVM (Figure 4A). In addition to the lack of MSP1 expression in PbΔfabI
parasites, nuclear division was clearly impeded, as evidenced by the limited number of DAPI-
positive parasite nuclei (Figure 4A). The very few MSP1-positive PbΔfabI liver stage parasites
that we did observe were restricted in size, with minimal PPM invaginations (Figure 4A; Figure
S5A). In support of this, at 60–65 hr post-invasion we recorded no cytomere stage in over 3,500
PbΔfabI liver stage parasites, whereas cytomeres were observed in 266 ANKA parasites out
of a total of 3,366. At these late stages of parasite development, ANKA parasites began to
degrade the PVM, as evidenced by their lack of the typical Exp1-positive closed circular
structures seen in earlier stages (Figure S5B). This resulted in the generation of large clusters
of MSP1-positive merozoites that filled the entire hepatocyte cytoplasm. Of these PVM-
degraded ANKA-infected cells, 87% contained MSP1-positive merozoites. The remaining
13% were MSP1-negative, suggesting that these had undergone aberrant development and had
failed to produce viable merozoites (Figure S5B). In contrast, every PbΔfabI parasite that was
found to have a non-intact PVM was MSP1-negative and was not producing mature merozoites
(Figure S5B).
At the 65 hr time point, we also recorded the numbers of infected cells that had detached from
the monolayer into the culture supernatant. These so-called “detached cells” harbor merozoites
that have been released into the host cell cytoplasm following normal degradation of the PVM
(Sturm et al., 2006). In three independent experiments, we did not observe a single detached
cell with the PbΔfabI parasites. In contrast, detached cells numbered 210, 236 and 106 with
ANKA parasites and 298, 136 and 103 with PbfabIRec parasites (Figure 4B). From these
cultures, we also recorded the number of merosomes, i.e. the membrane-bound clusters of
merozoites devoid of host nuclei that egress from the infected hepatocytes (Sturm et al.,
2006; Sturm et al., 2008). Merosomes were never observed in PbΔfabI liver stage cultures in
any of these three experiments. By comparison, ANKA parasites produced 69, 174 and 41
merosomes, while PbfabIRec parasites produced 77, 68 and 13 merosomes respectively (Figure
4B). Similar results were obtained in three additional experiments that examined liver stage
parasites 70 hr post-invasion (data not shown), confirming a key role for FabI during the final
maturation of the liver stage schizont and the formation of merozoites.
While we never observed PbΔfabI merosomes, even after an extended culture period of 90 hr,
we nevertheless recorded rare instances of MSP1-positive PbΔfabI merozoites. We also
observed one instance of a cytomere stage at 70 hr post-invasion. The formation of these few
merozoites and their passage into the blood stream might account for the PbΔfabI breakthrough
blood stage infections observed in vivo.
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DISCUSSION
Here we report on the discovery that the FAS-II enzyme FabI plays a key role in the
development of infectious liver stage merozoites. Our study reveals a fundamental difference
in how Plasmodium liver and asexual stage parasites balance de novo synthesis and salvage of
host factors to meet their FA requirements for intracellular parasite propagation. For asexual
blood stages, our findings provide evidence against a recent report of an active FAS-II pathway
(Surolia and Surolia, 2001), and instead support an alternate mechanism of FA modification
that appears to act alongside a predominant import pathway.
The asymptomatic liver stage begins with SPZ productively infecting hepatocytes
(Mikolajczak and Kappe, 2006; Prudencio et al., 2006). Following a prodigious phase of
nuclear replication, parasites enter the cytomere stage wherein nuclei distribute peripherally
beneath the invaginating inner PPM. Later, the outer PVM disintegrates, releasing merozoites
into the host cell cytoplasm. This process in vitro leads to cell detachment, followed by the
destruction of host cell organelles including the nucleus, and the formation of a host cell
membrane-bounded merosome that is able to initiate a blood stage infection (Sturm et al.,
2006). Studies with PbΔfabI revealed a striking defect in liver stage maturation. Whereas cell
traversal, invasion, and initial development inside a parasitophorous vacuole proceeded
normally, late PbΔfabI liver stage parasites displayed a pronounced absence of the MSP1
parasite surface protein in the PPM. Furthermore, these parasites almost completely failed to
develop to the cytomere stage, could not normally degrade their PVM, and exhibited an
impaired development of merozoites. PbΔfabI parasites also displayed a near total lack of cell
detachment and merosome formation (Figure 4; Figure S5). We posit that this developmental
arrest explains the attenuated infectivity of PbΔfabI SPZ, as illustrated by their substantially
delayed progression to blood stage infection (Table 2). Residual infectivity was nevertheless
observed, especially with the higher doses of 104 PbΔfabI SPZ that produced blood stage
infections in most mice. These “breakthrough” infections were fulminant and lethal, indicating
that the few parasites that completed their liver stage development were not attenuated for
asexual blood stage growth.
Dr. Stefan Kappe (Seattle Biomedical Research Institute) and colleagues have observed a
similar phenotype of late liver stage arrest upon deletion of the FAS-II gene fabB/F in P.
yoelii 17XNL. Their analysis of infected hepatocytes, obtained in BALB/c mice inoculated 44
hr prior with fabB/F knockout SPZ, revealed a lack of MSP1 staining and merozoite formation
as well as a defect in PVM degradation (based on Hep17 expression), when compared to WT
liver stage parasites. In agreement with our observations, no attenuation was evident at other
life cycle stages for both P. yoelii fabB/F knockout parasites and a further knockout line that
carried a deletion of fabZ. In contrast to PbΔfabI SPZ, the P. yoelii fabB/F knockout line failed
to produce breakthrough asexual blood stage infections, even with an inoculum as high as
100,000 salivary gland SPZ (S. Kappe, pers. comm.). This might reflect differences in the
virulence of the erythrocytic stages of P. berghei ANKA versus P. yoelii 17XNL. P. berghei
ANKA parasites are known to rapidly produce a fulminant, lethal infection starting from low
numbers of infected RBC. In contrast, P. yoelii 17XNL infections are non-lethal and can be
readily resolved by host immune responses. Alternatively, these species might differ in their
dependence on FAS-II for successful liver stage development.
Taken together, the FAS-II gene disruption data make a compelling case that de novo FA
biosynthesis plays a key role in the successful production of the thousands of infectious
merozoites produced per infected hepatocyte. While it is possible that FAS-II provides unique
(i.e. unsalvageable) FA, the detection of breakthrough infections with PbΔfabI suggests that
its role is predominantly to augment levels of salvaged FA to meet metabolic demands. Insights
into the potential utilization of FAS-II products are provided by our investigations with
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PbΔfabI. These parasites revealed a pronounced deficit in their expression of MSP1, which is
anchored to the parasite membrane via GPI moieties. These moieties are enriched in C16:0
(palmitic acid), C18:0 (stearic acid) and C18:1 (oleic acid) (Naik et al., 2000). How could these
be produced by the liver stage parasite? Biochemical studies with purified P. falciparum FAS-
II enzymes provide evidence that this pathway produces predominantly C10 to C14 FA (Sharma
et al., 2007). To modify these species into the saturated and unsaturated FA found in GPI
anchors would require the further action of elongases and desaturases (see below), whose
activity in liver stage parasites has been detected (Tarun et al., 2008). The inability of
PbΔfabI liver stage parasites to form cytomeres and normally degrade their PVM suggests that
FAS-II products might also be incorporated into neutral glycerolipids, which have been
implicated in intracellular vesicle trafficking, and membrane-resident phospholipids (Palacpac
et al., 2004). Likewise, the failure of PbΔfabI-infected hepatocytes to form detached cells
suggests that FAS-II products might contribute to parasite manipulation of the phospholipid
composition of host cell membranes, a mechanism that appears to subvert immune recognition
by liver phagocytes and that correlates with in vitro cell detachment (Sturm et al., 2006). This
proposed central role of FA in liver stage biology agrees with recent transcriptome data showing
that all four P. yoelii FAS-II genes are highly expressed in liver stages, as compared to SPZ or
asexual blood stages (Tarun et al., 2006). Those studies also revealed upregulation of members
of the pyruvate dehydrogenase complex, whose production of acetyl-CoA primes the FAS-II
pathway (Mazumdar and Striepen, 2007). These studies evoke the idea of targeting FAS-II
enzymes for the development of a novel prophylactic antimalarial drug that clears liver stage
infections before they advance to the pathogenic erythrocytic stages.
In contrast to the phenotype of late liver stage arrest observed upon disruption of the FAS-II
pathway, other Plasmodium gene disruption studies have produced much earlier arrest. Dual
disruption of the P. yoelii genes p36 and p52 (also termed p36p), individual knockouts of their
orthologs in P. berghei, disruption of the sap1/slarp gene in P. yoelii and P. berghei, and
disruption of the P. berghei uis4 or uis3 genes all produced a developmental block within 24–
48 hr post invasion ((Aly et al., 2008; Silvie et al., 2008a); and references therein). Of the
genetically attenuated SPZ, those that did not cause breakthrough asexual blood stage
infections were found to elicit complete protective immunity against challenge with non-
attenuated SPZ. We did not perform similar studies because of the finding that PbΔfabI SPZ
could produce breakthrough parasitemias. Nevertheless, when compared to the other knockout
lines, the delayed demise of PbΔfabI liver stage parasites provides a greater window of antigen
presentation, suggesting a potentially enhanced degree of immunogenicity (Jobe et al., 2007).
Furthermore, given that the human parasite P. falciparum has a prodigious growth phase inside
hepatocytes, on the order of 10,000–30,000 merozoites per infected cell as compared to 8,000–
10,000 per hepatocyte for P. berghei and P. yoelii (Verhave and Meis, 1984), one might predict
that the inability to produce sufficient levels of FA through de novo synthesis could be severely
detrimental for P. falciparum. Interestingly, the P. berghei PVM resident protein UIS3 has
been shown to bind L-FABP (liver-fatty acid binding protein), a key mediator of cellular uptake
and transport of the FA and lipid species that are abundant in hepatocytes (Furuhashi and
Hotamisligil, 2008). This leads us to hypothesize that the disruption of liver stage FA de
novo synthesis and import might yield potent, genetically attenuated pre-erythrocytic stage
vaccines in Plasmodium species including P. falciparum.
Though the FAS-II pathway appears vitally important to liver stage parasites, the analysis of
our PfΔfabI and PbΔfabI lines argues against the earlier hypothesis that this pathway is required
for asexual blood stage propagation (Surolia et al., 2004). An alternative explanation of our
data would be that another enoyl ACP-reductase might have compensated for the loss of FabI
and thereby restore FAS-II functionality to the ΔfabI lines during their life cycle. Our
bioinformatic search for alternate bacterial enoyl-ACP reductases (FabK, FabL and FabV;
(Massengo-Tiasse and Cronan, 2008)) fail to identify any orthologs in Plasmodium, although
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this does not rule out their potential existence. Nonetheless, the blood and liver stage
phenotypes we observe with our ΔfabI lines have also been observed by Stefan Kappe and
colleagues with transgenic P. yoelii parasites that lack fabB/F or fabZ (pers. comm.). Again,
we have not found paralogs of these genes through bioinformatic searches of Plasmodium
genomes. Our data therefore are consistent with a lack of requirement for the FAS-II pathway
in asexual blood stage parasites and support earlier evidence that these stages rely on salvage
pathways for the bulk of their FA requirements (Vial and Ancelin, 1992).
In a remarkable body of work, Mi-Ichi et al. (Mi-Ichi et al., 2007; Mi-Ichi et al., 2006) found
that several combinations including C16:0/C18:0/C18:2,n-6 or C16:0/C18:1,n-9/C18:2,n-6 were
sufficient to replace human serum or Albumax in malaria culture medium and permitted robust
parasite growth for over 6 months. These various FA are the predominant species present in
human plasma and infected RBC (Mi-Ichi et al., 2006). As per earlier reports (Krishnegowda
and Gowda, 2003; Vial and Ancelin, 1992), these authors observed that salvaged FA are
predominantly incorporated in an unmodified form into parasite lipids. In addition, they
observed FA modification via elongation or desaturation processes. This included the
production of C16:0 and C18:0 from exogenous [14C]-C14:0 and [14C]-C16:0 respectively, and
desaturation of C18:0 to C18:1 (Mi-Ichi et al., 2006). In agreement with these findings, we also
observed C16 and C18 FA when incubating P. falciparum parasites with [14C]-acetate, with no
detectable difference between lines harboring or lacking FabI (Figure 3; Figure S2D). We also
observed no such incorporation in control uninfected RBC.
P. falciparum asexual blood stage production of radiolabeled C16 and C18 FA might involve
elongases, three of which are encoded by this genome (Lee et al., 2007). The presence of four
distinct elongases in the P. berghei genome might explain why this species was found to
produce C12 to C24 FA (Figure 3). These ER-resident enzymes are responsible in mammals
for producing very long chain FA (≥C18) and in trypanosomes produce C10 to C18 FA
(Jakobsson et al., 2006; Lee et al., 2006). P. falciparum asexual blood stages are also capable
of modifying FA via desaturation of C16:0 and C18:0 at the n-9 position, presumably via their
Δ–9 desaturase (PFE0555w; (Mi-Ichi et al., 2006)). Another crucial step in the intraerythrocytic
modification of imported host FA may involve acyl-CoA synthetase enzymes, which activate
acyl chains for entry into FA synthesis, desaturation, and elongation pathways. Members of
this gene family are present in 4–12 copies in Plasmodium species, and biochemical assays
have shown 20–fold higher acyl-CoA synthetase activity in infected versus uninfected RBC
(Bethke et al., 2006; Vial and Ancelin, 1992).
FabI has been extensively studied as a candidate drug target for asexual blood stage parasites.
Yet our data now argue against the therapeutic potential of this target, and indeed the entire
FAS-II pathway, during erythrocytic infection. These data imply that, contrary to earlier
suppositions (Ralph et al., 2004; Surolia et al., 2004), asexual blood stage parasites do not
require FAS-II activity in the apicoplast. Focusing on FabI, our transgene over-expression and
gene disruption studies demonstrate that this is not the target of the antimalarial activity of
triclosan (Figure 2 and Figures S1, S2 and S4), despite an earlier report of its inhibition of FA
biosynthesis in asexual blood stage parasites and its high affinity for purified enzyme (Perozzo
et al., 2002; Surolia and Surolia, 2001). These data agree with studies of Trypanosoma
brucei parasites that discount FabI as the target of triclosan and have proposed non-specific
membrane perturbation as an alternate mode of action (Lee et al., 2007). Our studies
nevertheless find that triclosan has activity against Plasmodium asexual blood stage parasites,
and is efficacious in vivo (Figure 1), albeit at concentrations substantially higher than
previously reported (Surolia and Surolia, 2001). Further studies are required to elucidate how
triclosan acts upon asexual blood stage parasites. In these stages, it is now clear that exogenous
FA are essential. We propose that therapeutic strategies to interfere with FA processes in
asexual blood stage parasites should focus on import and subsequent modification, presumably
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mediated by elongases, the Δ-9 desaturase, and acyl CoA-synthetases. This contrasts with liver
stage parasites where interference with FAS-II offers novel perspectives for prophylactic
intervention.
EXPERIMENTAL PROCEDURES
Parasite Propagation
P. falciparum lines (Table 1) and P. berghei ANKA parasites were propagated as described in
the Supplemental Data. All experiments involving rodents were conducted in fully accredited
animal facilities and were approved by the Institutional Animal Care and Use Committees of
Columbia University, the Albert Einstein College of Medicine, the New York University
Medical Center, the University of Miami and the Bernhard Nocht Institute for Tropical
Medicine.
Parasite in vitro and in vivo Drug Susceptibility Assays
The synthesis of triclosan analogs has been previously described ((Freundlich et al., 2007) and
references therein). For enzyme inhibition assays, the reaction mixtures contained 50 nM
PfFabI, 400 μM NADH and 40 μM NAD+, and were initiated with 300 μM butyryl-CoA.
Inhibition of PfFabI–mediated butyryl-CoA reduction was assessed spectrophotometrically by
measuring the oxidation of NADH to NAD+ at 340 nm (Freundlich et al., 2007). EC50 values
represent the analog concentration that inhibited maximal PfFabI activity by 50%. Inhibition
of P. falciparum in vitro or P. berghei ex vivo parasite growth was measured using [3H]-
hypoxanthine assays, and the IC50 values calculated using linear regression (see Supplemental
Data). All compounds were tested in duplicate on at least two separate occasions. For in vivo
efficacy studies, CD-1 mice were infected intraperitoneally on day 0 with 5 × 104 P. berghei
asexual blood stage parasites. Triclosan (Vita-Pharm, Valhalla, NY) was administered on days
3, 4 and 5 after infection, as two divided doses daily spaced 6 hr apart delivered either PO or
SC. Parasitemias were determined from Giemsa-stained smears of tail blood, collected on day
6 and twice a week thereafter until day 31 (see Supplemental Data).
Plasmid Constructs, Parasite Transfections, Nucleic Acid and Protein Analyses,
Immunofluorescence Assays, and Structural Elucidation of PbFabI
These are detailed in the Supplemental Data. Primers are listed in Table S2 and transfection
plasmids and parasite lines are listed in Table 1.
FA extraction and HPLC analysis
P. falciparum- or P. berghei-infected RBC were labeled with [14C]-acetate (10 μCi/ml) for 6
hr or 24 hr respectively at 37°C. Parasite pellets were obtained by saponin lysis, washed twice
to remove host cell components, and the FA analyzed by reversed-phase HPLC (see
Supplemental Data).
P. berghei Infection of Mosquitoes, Sporozoite Invasion and Cell Traversal Assays, and
Analysis of Liver Stage Development
Experimental conditions are detailed in the Supplemental Data.
Determination of P. berghei Prepatent Periods in Mice
To determine the in vivo infectivity of mutant and control parasite lines, naïve C57BL/6 mice
were injected intravenously with 1,000 or 10,000 P. berghei salivary gland SPZ, or subjected
to the bite of 20 infected mosquitoes that were allowed to probe for 6 min. Asexual blood stage
infection was determined by Giemsa-stained blood smears prepared on days 3 through 28 after
SPZ inoculation.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Glossary
ACP  
acyl carrier protein
CoA  
Coenzyme A
FA  
fatty acids
FAS-II  
type II fatty acid biosynthesis
GPI  
glycosylphosphatidylinositol
HPLC  
High Performance Liquid Chromatography
PO  
per oral
PPM  
parasitophorous plasma membrane
PVM  
parasitophorous vacuole membrane
RBC  
red blood cells
SC  
subcutaneous
SPZ  
sporozoites
WT  
wild type
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Figure 1. Triclosan Displays In Vitro Activity Against P. falciparum that Does Not Correlate with
Inhibition of FabI and is Less Effective in Curing Rodent Malaria Than Previously Reported
(A) Inhibitory activity of subclasses of triclosan analogs against P. falciparum lines and
purified PfFabI enzyme. (B) Log scale scatter plot of the activity of triclosan and its analogs
against P. falciparum 3D7 parasites and purified PfFabI, showing the Pearson r2 goodness of
fit value. The inset shows triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol) with carbon
atoms numbered where substitutions were made. (C) Percent parasitemias plotted for the
groups of mice receiving varying doses of triclosan, administered either orally (PO) or
subcutaneously (SC) twice daily for three days. Mean values (±SEM) were calculated from
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groups of 7–8 mice tested on two separate occasions. (D and E) Kaplan-Meier survival curves
for the groups receiving daily triclosan doses as indicated.
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Figure 2. Transgenic Expression of Mutant pffabI Does Not Confer Triclosan Resistance In Vitro
(A and B) Fluorescence microscopy of PffabI(A217V)Dd2 parasites. Proper targeting of
PfFabI-V5 to the apicoplast was illustrated by colocalization of the V5 epitope tag of the mutant
protein and acyl carrier protein (ACP). This signal was adjacent to the mitochondrion that was
visualized using MitoTracker Red (MT). Scale bar, 5 μm. DIC, Differential Interference
Contrast; HT, Hoechst 33342 nuclear dye; α-V5 and α-ACP, antibodies to V5 and ACP. Similar
results were obtained with PffabI(WT)Dd2 (data not shown) and with an earlier transgenic Dd2
line that expressed GFP-tagged PfFabI from the same calmodulin promoter (Nkrumah et al.,
2006). (C) Inhibitory activity of triclosan against P. falciparum lines expressing either mutant
or WT PfFabI. Data were derived from 3 separate experiments performed in duplicate. Lanes
(with mean±SEM IC50, IC90 values in μM) 1: PffabI(A217V)Dd2 (2.8±0.7, 6.9±0.4); 2: PffabI
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(WT)Dd2 (2.5±0.7; 7.3±0.7); 3: Dd2attB (3.1±0.7, 7.2±0.7); 4: PffabI(A217V)3D7 (2.1±0.4, 4.2
±0.3); 5: PffabI(WT)3D7 (2.0±0.3, 4.5±0.7); 6: 3D7attB (2.1±0.2, 4.8±0.6). (D) Northern blot
analysis showing presence of pffabI transcripts only in the lines expressing this transgene from
the calmodulin promoter. EtBr, ethidium bromide. Lanes 1: PffabI(A217V)Dd2; 2: PffabI
(WT)Dd2; 3: Dd2attB; 4: Dd2; 5, PffabI(A217V)3D7; 6, PffabI(WT)3D7; 7: 3D7attB; 8: 3D7.
ef-1α was used as a loading control. (E) Evidence that α-PfFabI and α-V5 antibodies recognize
the same protein in asexual blood stage parasites expressing calmodulin promoter-driven
PfFabI. Lanes 1 and 3: PffabI(A217V)Dd2; 2: PffabI(WT)Dd2 (these lines express PfFabI with
a V5 epitope). (F) Western blot analysis showing the detection of PfFabI only in the lines
expressing pffabI transgenes from the calmodulin promoter. α-PfERD2 antibodies were used
as a loading control. Lanes 1–8 are the same as in panel D.
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Figure 3. Plasmodium Asexual Blood Stage Parasites Modify FA in the Absence of FabI
HPLC analysis of extractable FA p-bromophenyacyl esters from in vitro cultures of the P.
falciparum lines (A) PfΔfabI1 and (B) Dd2, or ex vivo cultures of the P. berghei lines (C)
PbΔfabI and (D) ANKA. Acyl chain lengths are indicated. CPS, counts per second.
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Figure 4. P. berghei PbΔfabI Parasites Exhibit a Strongly Impaired Merozoite Development and
Fail to Form Detached Cells or Merosomes
(A) IFA results of ANKA and PbΔfabI liver stage parasites grown in vitro in HepG2 cells and
examined 60 hr post invasion. Parasites were stained with antibodies directed to Exp1 (green)
or MSP1 (red), and DAPI (blue) was used to label the parasite and host cell nuclei. (A)
Representative images of liver stage parasites developing within an intact PVM, as shown by
Exp1 staining as a closed circle around the nuclei. Percentages and numbers of MSP1 positive
or negative parasites were collated from three independent experiments. Results show that most
ANKA parasites (58.9%) developed normally and produced MSP1-positive merozoites,
whereas very few PbΔfabI parasites (0.5%) were MSP1-positive. The upper panel shows a
cytomere stage with typical membrane invaginations and arrangements of nuclei close to the
PPM. (B) For ANKA, PbΔfabI and PbfabIRec-infected HepG2 cells, the numbers of detached
cells and merosomes were quantified 65 hr post-invasion, in three independent experiments.
These revealed a total absence of detached cells and merosomes in PbΔfabI liver stage cultures.
Additional representative images are presented in Figure S5.
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